Floatz logo

74 assets in Estrogen-Receptor Positive Breast Cancer

Therapeutic assets addressing Estrogen-Receptor Positive Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Exemestane
Estrogen-Receptor Positive Breast Cancer
National Cancer Institute (NCI)P4BBB (75)
Everolimus
Estrogen-Receptor Positive Breast Cancer
UNC Lineberger Comprehensive Cancer CenterP4BBB (73)
Tamoxifen
Estrogen-Receptor Positive Breast Cancer
Dana-Farber Cancer InstituteP4BB (71)
Abemaciclib
Estrogen-Receptor Positive Breast Cancer
Jonsson Comprehensive Cancer CenterP3BB (70)
Capivasertib
Estrogen-Receptor Positive Breast Cancer
Imperial College LondonP2BB (70)
Giredestrant
Estrogen-Receptor Positive Breast Cancer
Hoffmann-La RocheP3BB (70)
Palbociclib
Estrogen-Receptor Positive Breast Cancer
Forward Pharmaceuticals Co., Ltd.P3BB (70)
Ribociclib
Estrogen-Receptor Positive Breast Cancer
National Cancer Institute (NCI)P3BB (69)
Cyclophosphamide
Estrogen-Receptor Positive Breast Cancer
UNC Lineberger Comprehensive Cancer CenterP2BB (68)
Elacestrant
Estrogen-Receptor Positive Breast Cancer
Kristina A. FanucciP3BB (68)
Adriamycin
Estrogen-Receptor Positive Breast Cancer
Baylor Breast Care CenterP2BB (67)
Fulvestrant
Estrogen-Receptor Positive Breast Cancer
Olema Pharmaceuticals, Inc.P3BB (67)
Durvalumab
Estrogen-Receptor Positive Breast Cancer
National Taiwan University HospitalP2BB (66)
Goserelin
Estrogen-Receptor Positive Breast Cancer
Memorial Sloan Kettering Cancer CenterP3BB (66)
Letrozole
Estrogen-Receptor Positive Breast Cancer
National Cancer Institute (NCI)P3BB (66)
Trastuzumab
Estrogen-Receptor Positive Breast Cancer
Dana-Farber Cancer InstituteP3BB (66)
Carboplatin
Estrogen-Receptor Positive Breast Cancer
UNC Lineberger Comprehensive Cancer CenterP2BB (64)
Ipatasertib
Estrogen-Receptor Positive Breast Cancer
Royal Marsden NHS Foundation TrustP2BB (64)
Palazestrant
Estrogen-Receptor Positive Breast Cancer
Olema Pharmaceuticals, Inc.P3BB (64)
Pertuzumab
Estrogen-Receptor Positive Breast Cancer
Dana-Farber Cancer InstituteP3BB (64)
Trastuzumab Deruxtecan
Estrogen-Receptor Positive Breast Cancer
Danish Breast Cancer Cooperative GroupP3BB (64)
Anastrozole
Estrogen-Receptor Positive Breast Cancer
National Cancer Institute (NCI)P3B (63)
Alpelisib
Estrogen-Receptor Positive Breast Cancer
Jennifer Lee Caswell-JinP2B (62)
Atezolizumab
Estrogen-Receptor Positive Breast Cancer
Hoffmann-La RocheP2B (62)
Pembrolizumab
Estrogen-Receptor Positive Breast Cancer
UNC Lineberger Comprehensive Cancer CenterP2B (61)
Dexasone
Estrogen-Receptor Positive Breast Cancer
MedSIRP3B (60)
Docetaxel
Estrogen-Receptor Positive Breast Cancer
Dana-Farber Cancer InstituteP2B (60)
Duloxetine
Estrogen-Receptor Positive Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTCP3B (60)
Furosemide
Estrogen-Receptor Positive Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTCP3B (60)
Tucatinib
Estrogen-Receptor Positive Breast Cancer
Dana-Farber Cancer InstituteP2B (60)
Hyaluronidase Zzxf
Estrogen-Receptor Positive Breast Cancer
Dana-Farber Cancer InstituteP2B (58)
Camizestrant
Estrogen-Receptor Positive Breast Cancer
AstraZenecaP1/2B (57)
Capecitabine
Estrogen-Receptor Positive Breast Cancer
UNC Lineberger Comprehensive Cancer CenterP2B (57)
Zotatifin
Estrogen-Receptor Positive Breast Cancer
Jennifer Lee Caswell-JinP2B (57)
Brc-001
Estrogen-Receptor Positive Breast Cancer
City of Hope Medical CenterP2CCC (53)
Coriolus Versicolor Extract
Estrogen-Receptor Positive Breast Cancer
Mayo ClinicP2CCC (53)
Datopotamab Deruxtecan
Estrogen-Receptor Positive Breast Cancer
Sarah Sammons, MDP2CCC (53)
Decitabine
Estrogen-Receptor Positive Breast Cancer
Virginia Commonwealth UniversityP2CCC (53)
Epirubicin
Estrogen-Receptor Positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityP2CCC (53)
Fes F-18
Estrogen-Receptor Positive Breast Cancer
City of Hope Medical CenterP2CCC (53)
Fludeoxyglucose
Estrogen-Receptor Positive Breast Cancer
University of WashingtonP2CCC (53)
Imlunestrant
Estrogen-Receptor Positive Breast Cancer
Jonsson Comprehensive Cancer CenterP2CCC (53)
Ketorolac
Estrogen-Receptor Positive Breast Cancer
Jules Bordet InstituteP2CCC (53)
Neratinib
Estrogen-Receptor Positive Breast Cancer
Massachusetts General HospitalP2CCC (53)
Olaparib
Estrogen-Receptor Positive Breast Cancer
UNICANCERP2CCC (53)
Omeprazole
Estrogen-Receptor Positive Breast Cancer
Jules Bordet InstituteP2CCC (53)
Pregabalin
Estrogen-Receptor Positive Breast Cancer
Jules Bordet InstituteP2CCC (53)
Pyrotinib
Estrogen-Receptor Positive Breast Cancer
Fudan UniversityP2CCC (53)
Replens
Estrogen-Receptor Positive Breast Cancer
Polly A. Niravath, MDP2CCC (53)
T-Dxd
Estrogen-Receptor Positive Breast Cancer
Guangzhou Women and Children's Medical CenterP2CCC (53)
Showing 1 to 50 of 74 assets
PreviousPage 1 of 2Next